[Click e-Stock] "Qurient Strengthens Platform with Adoption of Synaffix ADC Technology"

On September 26, Daishin Securities predicted that Qurient will maximize the value of its dual payload antibody-drug conjugate (ADC) platform based on its CDK7 inhibitor, Q901.

The previous day, Qurient signed a license agreement with Synaffix, a clinical-stage ADC platform company and subsidiary of Lonza, for the development of dual payload ADCs.

Kim Ahyoung, a researcher at Daishin Securities, explained, "By adopting Synaffix's ADC technology, Qurient will complete the CDK7 inhibitor and Synaffix's exatecan-based linker-payload ADC platform technology." She added, "Lonza, the parent company of Synaffix, will be responsible for production and technical support, which will enhance both the speed and quality of dual payload ADC development. It is assessed that preparations have been completed for the rapid technology transfer and commercialization of the dual payload ADC."

She stated, "Qurient will maximize the value of its dual payload ADC platform based on the CDK7 inhibitor Q901," and introduced, "The dual payload is a next-generation technology expected to overcome ADC resistance and enhance therapeutic efficacy."

Researcher Kim analyzed, "Currently, Jiangsu Hengrui Medicine and Innovent Biologics in China have entered clinical trials, and Qurient's first candidate, QP101, is a HER2-targeted dual payload ADC combining a CDK7 inhibitor and a TOP1 inhibitor." She further emphasized, "Compared to existing single payloads, it has demonstrated differentiation in the balance of efficacy and stability. The preclinical data is scheduled to be released at an academic conference in the fourth quarter of this year."

Kim also explained, "Another key pipeline of Qurient, Adricetnib (Q702), is strategically being developed for the cGvHD (chronic graft-versus-host disease) indication, securing the possibility of rapid technology export and product approval."

This content was produced with the assistance of AI translation services.